WallStreetZenWallStreetZen

NASDAQ: RARE
Ultragenyx Pharmaceutical Revenue

OverviewForecastEarningsRevenue
DividendOwnership
Ultragenyx Pharmaceutical revenue was $590.69M for the trailing 12 months ending Mar 31, 2025, with N/A growth year over year. Quarterly revenue for the quarter (Q1 2025) ending on Mar 31, 2025 was $139.3M, down 15.5% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, RARE annual revenue was $560.2M, with 29% growth year-over-year.

RARE past revenue growth

How has RARE's revenue growth performed historically?

Company
33.46%
Industry
1,361.15%
Market
34.96%
RARE's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
RARE's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Market Performance
RARE's revenue growth is slowing... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

RARE revenue history

Current Revenue
$590.7M
Current Earnings
-$549.6M
Current Profit Margin
-93%

Be the first to know when RARE announces revenue.

RARE Revenue History By Year

RARE Yearly RevenueRARE RevenueRARE ChangeRARE Revenue Growth
2024-12-31$560.23M$125.98M+29.01%
2023-12-31$434.25M$70.92M+19.52%
2022-12-31$363.33M$11.92M+3.39%
2021-12-31$351.41M$80.38M+29.66%
2020-12-31$271.03M$167.32M+161.32%
2019-12-31$103.71M$52.22M+101.41%
2018-12-31$51.50M$48.88M+1,871.48%
2017-12-31$2.61M$2.48M+1,863.91%
2016-12-31$133.00kN/AN/A
2015-12-31$0.00N/AN/A
2014-12-31$0.00N/AN/A
2013-12-31$0.00N/AN/A
2012-12-31$0.00N/AN/A
2011-12-31$0.00N/AN/A

1 of 1

Ultragenyx Pharmaceutical Revenue FAQ

What was RARE's revenue last quarter?

On Invalid Date, Ultragenyx Pharmaceutical (NASDAQ: RARE) reported Q1 2025 revenue of $139.29 million up 27.99% year over year. In the same quarter last year, Ultragenyx Pharmaceutical's revenue was $108.83 million.

What was Ultragenyx Pharmaceutical's revenue in 2024?

Ultragenyx Pharmaceutical's annual revenue for the twelve months ending Dec 31, 2024 was $560.23 million, a 29.01% increase year over year.

How much does Ultragenyx Pharmaceutical make in a day?

Based on Ultragenyx Pharmaceutical annual revenue for the past five years, RARE makes an average of $1,085,065.21 per day.

What was Ultragenyx Pharmaceutical's annual revenue growth in the past year?

As of Q2 2025, Ultragenyx Pharmaceutical's revenue has grown 33.46% year over year. This is 1,327.68 percentage points lower than the US Biotechnology industry revenue growth rate of 1,361.15%. Ultragenyx Pharmaceutical's revenue in the past year totaled $590.69 million.

How much does Ultragenyx Pharmaceutical make in a year?

Ultragenyx Pharmaceutical's revenue by year for the past five years is:
  • Ultragenyx Pharmaceutical's revenue for the twelve months ending Dec 31, 2024 was $560.23 million, a 29.01% increase year over year.
  • Ultragenyx Pharmaceutical's annual revenue for Dec 31, 2023 was $434.25 million, a 19.52% increase from 2022.
  • Ultragenyx Pharmaceutical's annual revenue for 2022 was $363.33 million, a 3.39% increase from 2021.
  • Ultragenyx Pharmaceutical's annual revenue for 2021 was $351.41 million, a 29.66% increase from 2020.
  • Ultragenyx Pharmaceutical's annual revenue for 2020 was $271.03 million, a 161.32% increase from 2019.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.